Word: costes
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...Missouri Ozarks with a mile of shoreline. To some, "rested" is just a way of saying that the camps will be sold. "It's difficult, but it's necessary to ensure the future of this organization," says Girl Scout spokeswoman Gina Garvin of the Kansas City area. Camps cost the council $1.7 million last year, so something has to give, she explains...
...attending camp. In New Jersey, three councils merged into a single group with six camps - two of which weren't being used much. Those two probably won't operate next summer, says Mary Connell, CEO of Girl Scouts of Central and Southern New Jersey, which will do a cost-benefit analysis of all the region's camps...
...Such tactics may help fatten corporate profits, but they hurt consumers, says Ilaria Passarani, health policy officer at the European consumer organization BEUC. "These measures represent a huge cost for patients and healthcare systems," she says. "These major drug companies should be focusing on innovative medicines, but this report says they actually spend 23% of turnover on marketing and promotional activities, a third more than the 17% they spend on research and development...
...European medicines market is worth over $175 billion. Europeans spend some $275 billion a year on pharmaceutical products - an average of $550 for every man, woman and child. But generic medicines can cost as much as 90% less than branded drugs: total savings gained by copycat drugs entry amounted to at least $17 billion over the 2000-2007 period examined by the Commission. Without these savings, the total expenditure for the medicines would have been more than 25% higher...
...Earlier this month, Ernst & Young took drugmakers to task for failing to meet changing market dynamics, such as an increasingly cost-averse customers. The industry faces unprecedented challenges related to patent expirations, pricing and regulatory pressures, shifting demographics, and globalization, yet most drug companies - particularly in Europe - have yet to adapt, Ernst & Young said...